Evidence map›Paper›PMID 38097236›Full record

ArticleBMJ open2023

Suicidality Treatment Occurring in Paediatrics (STOP) Medication Suicidality Side Effects Scale in young people in two cohorts across Europe.

Paramala Santosh, Regina Sala, Kate Lievesley, Jatinder Singh, Celso Arango, Jan K Buitelaar, Josefina Castro-Fornieles, David Coghill, Ralf W Dittmann, Itziar Flamarique and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 9 countries.

Paramala SantoshDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK paramala.1.santosh@kcl.ac.uk.ORCID 0000-0003-4830-5893
Regina SalaCentre for Psychiatry, Wolfson Institute, Barts & The London School of Medicine & Dentistry Queen Mary University of London, London, UK.
Kate LievesleyDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Jatinder SinghDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Celso ArangoChild and Adolescent Psychiatry Department, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Jan K BuitelaarDepartment of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands.
Josefina Castro-FornielesChild and Adolescent Psychiatry and Psychology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.
David CoghillDepartments of Paediatrics and Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.
Ralf W DittmannDept. of Child & Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Itziar FlamariqueChild and Adolescent Psychiatry and Psychology Department, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain.
Pieter J HoekstraDepartment of Child and Adolescent Psychiatry & Accare Child Study Center, University of Groningen, Groningen, The Netherlands.
Cloe LlorenteChild and Adolescent Psychiatry Department, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Diane Purper-OuakilHôpital Saint Eloi, Médecine Psychologique de l'Enfant et de l'Adolescent, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, Languedoc-Roussillon, France.
Ulrike SchulzeDepartment of Child and Adolescent Psychiatry/Psychotherapy, Universitatsklinikum Ulm, Ulm, Baden-Württemberg, Germany.
Alessandro ZuddasChild and Adolescent Neuropsychiatry Unit, Department of Biomedical Science, University of Cagliari, Cagliari, Italy.
Nathan ParnellDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Mohapradeep MohanDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Federico FioriDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
King's College London · GBAmerican Academy of Child and Adolescent Psychiatry · USHospital General Universitario Gregorio Marañón · ESHeidelberg University · DEInserm · FRQueen Mary University of London · GBRadboud University Nijmegen · NLRoyal Children's Hospital · AUUniversity Hospital Ulm · DEUniversity of Cagliari · ITUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAs part of the 'Suicidality: Treatment Occurring in Paediatrics (STOP)' study, we developed and performed psychometric validation of an electronic-clinical-outcome-assessment (eCOA), which included a patient-reported-outcome (ePRO), an observer-rated-outcome (eObsRO) for parents/carers and a clinician-reported-outcome (eClinRO) that allows identification and monitoring of medication-related suicidality (MRS) in adolescents.

designSTOP: Prospective study: A two phase validation study to assess the impact of medication on suicidal ideations.

settingSix participating countries: Netherlands, UK, Germany, France, Spain and Italy that were part of the Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261411.

participantsCohort 1 consisted of 41 adolescent-completions, 50 parent-completions and 56 clinician-completions. Cohort 2 consisted of 244 adolescent-completions, 198 parent-completions and 240 clinician-completions from across the six countries. The scale was administered only to participants who have screened positive for the STOP-Suicidality Assessment Scale (STOP-SAS).

resultsA total of 24 items for the development of the STOP-Medication Suicidality Side Effects Scale (STOP-MS

conclusionThese findings suggest that the STOP-MS

Indexed as

Suicidal IdeationSuicideAdolescentChildEuropeGermanyHumansPsychometricsReproducibility of Resultschild & adolescent psychiatrydevelopmental neurology & neurodisabilityinformation technologymental healthsuicide & self-harm

Identifiers

PMID38097236
PMCPMC10728977
OpenAlexW4389767116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.